Congestion - that bunged up, stuffy nose feeling - is usually a fleeting symptom of a cold which lasts for around a week and ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
Adult patients with severe CRSwNP treated with tezepelumab continued to receive benefit 24 weeks after treatment cessation.
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
The Family Health Care Institute bulletin (one of King Hussein Foundation's institutes), on this Sunday, discusses nasal and ...
Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published ...
1 Operating Room, Shaanxi Provincial People's Hospital, Xi'an, China 2 Department of Otolaryngology, Shaanxi Provincial People's Hospital, Xi'an, China Objective: To explore the blocking effect of a ...
1 Department of Otorhinolaryngology and Head and Neck Surgery, Mitsui Memorial Hospital, Tokyo, Japan 2 Department of Otorhinolaryngology and Head and Neck Surgery, Graduate School of Medicine and ...
CHMP backs AstraZeneca and Amgen’s therapy for chronic rhinosinusitis Tezspire (tezepelumab) has received a positive opinion from the CHMP for the treatment of chronic rhinosinusitis with nasal polyps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback